{"doi":"10.1038/s41598-021-84733-5","title":"Neutralization of SARS-CoV-2 with IgG from COVID-19-convalescent plasma","abstract":"<jats:title>Abstract</jats:title><jats:p>While there are various attempts to administer COVID-19-convalescent plasmas to SARS-CoV-2-infected patients, neither appropriate approach nor clinical utility has been established. We examined the presence and temporal changes of the neutralizing activity of IgG fractions from 43 COVID-19-convalescent plasmas using cell-based assays with multiple endpoints. IgG fractions from 27 cases (62.8%) had significant neutralizing activity and moderately to potently inhibited SARS-CoV-2 infection in cell-based assays; however, no detectable neutralizing activity was found in 16 cases (37.2%). Approximately half of the patients (~ 41%), who had significant neutralizing activity, lost the neutralization activity within ~ 1 month. Despite the rapid decline of neutralizing activity in plasmas, good amounts of SARS-CoV-2-S1-binding antibodies were persistently seen. The longer exposure of COVID-19 patients to greater amounts of SARS-CoV-2 elicits potent immune response to SARS-CoV-2, producing greater neutralization activity and SARS-CoV-2-S1-binding antibody amounts. The dilution of highly-neutralizing plasmas with poorly-neutralizing plasmas relatively readily reduced neutralizing activity. The presence of good amounts of SARS-CoV-2-S1-binding antibodies does not serve as a surrogate ensuring the presence of good neutralizing activity. In selecting good COVID-19-convalescent plasmas, quantification of neutralizing activity in each plasma sample before collection and use is required.</jats:p>","journal":"Scientific Reports","year":2021,"id":21420,"datarank":1.5876373421012855,"base_score":4.007333185232471,"endowment":4.007333185232471,"self_citation_contribution":0.6010999777848708,"citation_network_contribution":0.9865373643164146,"self_endowment_contribution":0.6010999777848708,"citer_contribution":0.9865373643164146,"corpus_percentile":null,"corpus_rank":null,"citation_count":54,"citer_count":25,"citers_with_citation_signal":20,"citers_with_endowment":20,"datacite_reuse_total":0,"is_dataset":false,"is_dataset_confidence":null,"is_data_producer":false,"deposit_databanks":null,"is_oa":false,"file_count":0,"downloads":0,"has_version_chain":false,"published_date":null,"fair_score":null,"fair_percentile":null,"algorithm_id":"datarank_citation_only_1hop_v6","ranking_scope":"data_only","authors":[{"id":137990,"name":"Nobuyo Higashi-Kuwata","orcid":null,"position":1,"is_corresponding":false},{"id":137991,"name":"Noriko Kinoshita","orcid":null,"position":2,"is_corresponding":false},{"id":137992,"name":"Satoshi Kutsuna","orcid":null,"position":3,"is_corresponding":false},{"id":137993,"name":"Kiyoto Tsuchiya","orcid":null,"position":4,"is_corresponding":false},{"id":137994,"name":"Shin-ichiro Hattori","orcid":null,"position":5,"is_corresponding":false},{"id":137995,"name":"Kouki Matsuda","orcid":null,"position":6,"is_corresponding":false},{"id":137996,"name":"Yuki Takamatsu","orcid":null,"position":7,"is_corresponding":false},{"id":137997,"name":"Hiroyuki Gatanaga","orcid":null,"position":8,"is_corresponding":false},{"id":12053,"name":"Shinichi Oka","orcid":"0000-0002-9283-2167","position":9,"is_corresponding":false},{"id":131441,"name":"Haruhito Sugiyama","orcid":null,"position":10,"is_corresponding":false},{"id":103444,"name":"Norio Ohmagari","orcid":"0000-0002-4622-8970","position":11,"is_corresponding":false},{"id":137998,"name":"Hiroaki Mitsuya","orcid":null,"position":12,"is_corresponding":false},{"id":137989,"name":"Kenji Maeda","orcid":null,"position":0,"is_corresponding":false}],"reference_count":0,"raw_metadata":{"has_enrichment":true,"base_score":4.007333185232471,"endowment":4.007333185232471,"datacite_reuse_total":0,"file_count":0,"downloads":0,"views":0,"has_version_chain":false,"is_dataset":false,"is_oa":false,"pmid":"33692457","pmcid":"PMC7946899","openalex_id":"https://openalex.org/W3133547117","authors":[],"funders":[{"funder_name":"Japan Agency for Medical Research and Development","grant_id":"JP20fk0108160","title":null}],"total_grants":1,"fwci":3.3244,"citation_percentile":0.93795847,"influential_citations":0,"citation_trend":[{"year":2021,"count":18},{"year":2022,"count":19},{"year":2023,"count":7},{"year":2024,"count":7},{"year":2025,"count":2},{"year":2026,"count":1}],"oa_status":"gold","license":"cc-by","oa_locations":[{"url":"https://www.nature.com/articles/s41598-021-84733-5.pdf","host_type":"journal"},{"url":"https://doi.org/10.1038/s41598-021-84733-5","host_type":"GOLD"},{"url":"https://www.nature.com/articles/s41598-021-84733-5.pdf","host_type":"publisher"},{"url":"https://www.nature.com/articles/s41598-021-84733-5","host_type":"publisher"},{"url":"https://pubmed.ncbi.nlm.nih.gov/33692457","host_type":"repository"},{"url":"https://doaj.org/article/970cba33ead34dc8a53bb58f6d2d522f","host_type":"repository"},{"url":"https://www.ncbi.nlm.nih.gov/pmc/articles/7946899","host_type":"repository"},{"url":"https://europepmc.org/articles/PMC7946899","host_type":"Europe_PMC"},{"url":"https://europepmc.org/articles/PMC7946899?pdf=render","host_type":"Europe_PMC"}],"fields_of_study":["SARS-CoV-2 and COVID-19 Research","COVID-19 Clinical Research Studies","SARS-CoV-2 detection and testing","Medicine","Adult","Aged","Aged, 80 and over","Antibodies, Neutralizing","Antibodies, Viral","COVID-19","Female","Humans","Immunization, Passive","Immunoglobulin G","Male","Middle Aged","Pandemics","Plasma","Receptors, Virus","SARS-CoV-2","COVID-19 Serotherapy"],"mesh_terms":["COVID-19","SARS-CoV-2","COVID-19 Serotherapy","Adult","Aged","Aged, 80 and over","Antibodies, Viral","Female","Humans","Immunoglobulin G","Immunization, Passive","Male","Middle Aged","Plasma","Receptors, Virus","Antibodies, Neutralizing","Pandemics"],"keywords":["Neutralization","Neutralizing antibody","Convalescent plasma","Antibody","Virology","Coronavirus disease 2019 (COVID-19)","Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)","Immune system","Immunology","Medicine","Internal medicine","Infectious disease (medical specialty)"],"sdg_mappings":[{"sdg_number":0,"sdg_label":"Good health and well-being"}],"linked_datasets":[],"clinical_trials":[],"software_tools":[],"database_accessions":[],"source":"live","citation_network_status":"fetched"},"created_at":"2026-06-06T15:51:24.733038Z","pmid":null,"pmcid":null,"fwci":null,"citation_percentile":null,"influential_citations":0,"oa_status":null,"license":null,"views":0,"total_file_size_bytes":0,"version_count":0,"fair_f":null,"fair_a":null,"fair_i":null,"fair_r":null,"fair_zscore":null,"fair_rationale":null,"fair_model":null,"fair_agent_version":null,"fair_fulltext_source":null,"fair_has_llm":null,"fair_computed_at":null,"clinical_trials":[],"software_tools":[],"db_accessions":[],"linked_datasets":[],"topics":[]}